千金女佣

葡萄牙记者：尽管现在的穆里尼奥年岁渐长，但他的本质依然未变_我的网站

A |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。    8月26日讯 据塞尔电台报道，对阵皇家社会的比赛，将是穆里尼奥时隔13年后再次在伯纳乌球场执教。他此次回归皇马所呈现出的形象，与人们记忆中他上一次执教时的样子大相径庭。他显得更加沉稳，不再那么咄咄逼人——这或许是岁月与阅历沉淀后的成熟，他甚至能与当年曾发生过激烈冲突的记者们开玩笑了。然而，曾亲眼见证这位来自塞图巴尔的主帅执教本菲卡时期的葡萄牙记者路易斯·克里斯托旺，却对这个所谓的“新穆里尼奥”持谨慎态度。这位记者被问到了一个直截了当的问题：穆里尼奥在这13年间真的改变了吗？“与早期的那个他相比，是的，他变了。他经历了许多风雨，在某种程度上也曾远离世界足坛的顶级舞台，而如今他又重返其中，”这位葡萄牙记者解释道。他还指出，目前在皇马训练基地（巴尔德贝巴斯）发生的一切，与当年他在葡萄牙的情形如出一辙。“当年他刚到本菲卡时，我们也有完全相同的感觉。他看起来变了，像换了个人似的。他变得更友善、更沉稳，还谈论起那些改变了他的经历，”他解释说。不过，克里斯托旺也发出了明确的警示——这对于那些关键时刻到来、且战绩不尽如人意的情形尤为重要：“但他初来乍到是一回事，而当周围的局势、外界的质疑以及比赛本身变得愈发艰难时，情况就完全不同了。就这一点而言，我想说的是，尽管现在的穆里尼奥年岁渐长，但他的本质依然未变。”身在葡萄牙的克里斯托旺也感到难以置信：皇马竟然选择在13年后重新请回穆里尼奥执教。“他能重返马德里让我非常惊讶，”他解释道，“因为上赛季离开费内巴切后，我曾说过，他重返里斯本（执教本菲卡）将是他最后的机会。

B | ”他补充道：“那是他最后一次机会去执教豪门、征战欧冠并成就一番伟业——在职业生涯临近尾声之际留下属于自己的印记。”然而，皇马的机会就这样出现了。鉴于种种情况，克里斯托旺对这一任命感到震惊——尤其是考虑到他在里斯本执教本菲卡期间的口碑：“他在那里的表现既不惊艳，也谈不上出色，如今重返马德里简直不可思议。这完全出人意料。”本周三，穆里尼奥将重返伯纳乌，面对一个截然不同的主场环境。

C | 然而，或许他自己却依然如故，未曾改变。

Current article:http://3gw.ningshunsaotuiqiao.shop/list_8bx/uxohl.html

Published on:21:26:49